GLP-1 price competition for uninsured patients: real or wishful thinking?

What's this video probably claiming?

Based on the caption, Dr. Alfery appears to be making the case that Novo Nordisk and Eli Lilly are finally starting to compete for uninsured and out-of-pocket patients by offering lower-cost access to semaglutide (Wegovy) and tirzepatide (Zepbound). He seems cautiously optimistic, acknowledging prices remain high but predicting they will fall as competitive pressure builds. This is a topic worth examining carefully, because the reality of GLP-1 pricing is messier than a simple supply-and-demand story. Novo Nordisk launched a $499/month direct-to-consumer program for Wegovy in late 2024 through NovoCare, and Eli Lilly has offered Zepbound vials at reduced prices through its own direct program. These moves are real, but they come with significant strings attached that a 60-second TikTok may not fully capture.

What does the science actually show?

The clinical case for these drugs is not in dispute. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean weight loss of 20.9% over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced 14.9% weight loss over 68 weeks. These are genuinely large effect sizes by obesity pharmacotherapy standards. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular mortality reduction data for semaglutide, which expanded insurer interest but has not yet reliably translated into broader coverage for weight loss specifically. The efficacy data is strong. The access data is not. A 2023 analysis in Health Affairs estimated fewer than 25% of commercially insured Americans have coverage for anti-obesity medications, and uninsured patients face list prices of $900-$1,400 per month without assistance programs.

Where does the social media noise diverge from clinical reality?

The optimism about price competition is understandable but probably premature. Eli Lilly's self-pay vial program prices Zepbound at $399-$549/month depending on dose, which is a real reduction but still out of reach for most uninsured Americans. Novo Nordisk's $499 program has eligibility restrictions and does not apply to pharmacy benefit plans. Neither program represents a structural shift in how these drugs are priced or distributed. Patent protection on semaglutide runs through at least 2032 in the US, and tirzepatide's core patents extend similarly. The FDA's crackdown on compounded semaglutide in 2024, after removing it from the shortage list, removed a major low-cost alternative that millions of patients had been using. Framing this as a competitive pricing revolution may overstate where things actually stand today.

What should you actually know?

If you are uninsured and considering a GLP-1 receptor agonist for weight management, here is what the current landscape actually looks like. Manufacturer savings programs exist but have income caps and eligibility criteria, and they can be discontinued at any time. Compounded versions are facing increasing legal and regulatory pressure, and FDA has explicitly stated compounded semaglutide is not equivalent to FDA-approved Wegovy or Ozempic. Telehealth platforms can legitimately prescribe these medications, but patients should verify they are receiving FDA-approved formulations. The price trajectory may eventually improve, particularly if biosimilar semaglutide reaches the US market, but analysts at IQVIA and industry watchers at Endpoints News project meaningful price competition is likely 5-8 years away. For now, the self-pay programs are a small step, not a solution.

• Wegovy list price: approximately $1,349/month without insurance in 2024
• Zepbound self-pay vial program: $399-$549/month through Lilly Direct
• NovoCare patient assistance: $499/month program with eligibility restrictions
• Compounded semaglutide: FDA removed from shortage list in 2024, limiting legal compounding
• Biosimilar semaglutide: not yet approved in the US as of early 2025